Assignee
SUMITOMO DAINIPPON PHARMA ONCOLOGY INC
US·8 granted patents·14 pending applications·24 citations·filing 2017–2020
Top patents by PatentIndex Score
22 records- 0196US10835537B2Combination therapies for treatment of cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Granted Nov 17, 2020·7 cites·6 claims
- 0293US11034710B2CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted Jun 15, 2021·7 cites·28 claims
- 0391US11279694B2Alvocidib prodrugs and their use as protein kinase inhibitorsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2017·Granted Mar 22, 2022·6 cites·4 claims
- 0484US10875864B2Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitorsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted Dec 29, 2020·1 cites·28 claims
- 0580US11013741B1AXL kinase inhibitors and use of the sameSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted May 25, 2021·1 cites·11 claims
- 0680US10851075B2Stat3 pathway inhibitors and cancer stem cell inhibitorsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2018·Granted Dec 1, 2020·1 cites·3 claims
- 0776US11040038B2Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the sameSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted Jun 22, 2021·1 cites·11 claims
- 0874US2021024482A1Novel Group of STAT3 Pathway Inhibitors and Cancer Stem Cell Pathway InhibitorsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 0974US2021115006A1Novel compositions and methods for cancer treatmentSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1072US2021238183A1Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitorsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1171US2021052568A1Predicting response to alvocidib by mitochondrial profilingSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1271US2021002233A1Pkm2 modulators and methods for their useSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1369US2021070715A1Jak2 and alk2 inhibitors and methods for their useSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1468US2021228582A1Combination therapies for treatment of cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1561US2021113562A1Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 1651US2022162200A1Pkm2 modulators and methods for their useSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1750US2021277037A1Deuterated alvocidib and alvocidib prodrugsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 1848US11299469B2Naphthofuran derivatives, preparation, and methods of use thereofSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2017·Granted Apr 12, 2022·0 cites·22 claims
- 1948US2022380348A1Axl inhibitor formulationsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 2047US2022305037A1Treatment of CancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 2144US2022257581A1Treatment of CancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 2238US2021379042A1Methods for monitoring tumor lysis syndromeSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SUMITOMO DAINIPPON PHARMA ONCOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →